#1 Clinical Trials Search in Europe

Study on INZ-701 for Improving Survival in Infants with ENPP1 Deficiency

3 1 1

What is this study about?

The study focuses on a rare condition called Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, which affects infants. This condition can lead to serious health issues, including problems with the heart and the hardening of arteries. The treatment being tested is a medication known as INZ-701, which is a special type of protein designed to help manage this deficiency. The purpose of the study is to see if INZ-701 can increase the levels of a substance called inorganic pyrophosphate (PPi) in the body and improve the overall survival of infants with this condition.

During the study, infants will receive INZ-701 through a subcutaneous injection, which means it is given under the skin. The study will observe the infants over a period of time to see how their bodies respond to the treatment. Researchers will monitor changes in the infants’ health, including heart function and growth, to determine the effectiveness and safety of the treatment. The study will also compare the results with those of infants who do not receive the treatment to understand its impact better.

The study aims to provide valuable information on whether INZ-701 can help prevent heart dysfunction and the calcification of arteries in infants with ENPP1 Deficiency. By increasing the levels of PPi, the treatment may offer a new way to manage this challenging condition and improve the quality of life for affected infants. The study will continue for a set period, allowing researchers to gather comprehensive data on the treatment’s long-term effects.

1 joining the study

Upon joining the study, the caregiver provides written or electronic consent after understanding the study details.

The infant must have a confirmed genetic diagnosis of ENPP1 Deficiency and meet specific health criteria.

2 initial assessment

An initial assessment is conducted to establish baseline health metrics, including plasma PPi concentration and other clinical evaluations.

3 treatment administration

The infant receives the study drug INZ-701 as a subcutaneous injection.

The medication is prepared from a lyophilized powder specifically for injection.

4 ongoing monitoring

Regular monitoring occurs to track changes in plasma PPi levels and overall health.

Health assessments include echocardiography to evaluate heart function and CT scans to check for vascular calcification.

5 evaluation of growth and development

The infant’s growth is monitored through measurements of body length and weight.

Growth velocity and other developmental milestones are assessed throughout the study.

6 completion of study

The study is expected to continue until February 2028, with regular assessments and data collection.

The primary focus is on changes in plasma PPi concentration and overall survival.

Who Can Join the Study?

  • The caregiver(s) must give written or electronic consent after the study has been explained to them, before any research-related procedures begin.
  • The patient must have a confirmed genetic diagnosis of ENPP1 Deficiency. This means they have specific changes in their genes, known as biallelic mutations (either both copies of a gene are the same, called homozygous, or each copy is different, called compound heterozygous). This diagnosis should be done using approved tests.
  • There must be clinical evidence of GACI (Generalized Arterial Calcification of Infancy), which can include symptoms like unusual calcium deposits in the body, heart failure, breathing problems, swelling, bluish skin color, high blood pressure, enlarged heart, or other related signs.
  • The study is open to both males and females from birth up to less than 1 year old at the start of the study.
  • The patient’s blood level of PPi (inorganic pyrophosphate) must be less than 1400 nM. This is checked at the study screening if the patient hasn’t been part of a previous program, or at a documented baseline before starting treatment with the study drug INZ-701.
  • The patient must weigh at least 0.5 kg at the time of the first dose of INZ-701.
  • The patient must be able to complete all parts of the study, as judged by the study doctor.
  • The caregiver(s) must agree to allow access to their infant’s relevant medical records.

Who Cannot Join the Study?

  • Patients with any other serious health condition that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial recently.
  • Patients who have allergies to the study medication or its ingredients.
  • Patients who are unable to follow the study procedures or instructions.
  • Patients with a history of substance abuse or addiction.
  • Patients who have had a major surgery recently.
  • Patients with certain heart conditions that could be affected by the study medication.
  • Patients with severe liver or kidney disease.
  • Patients who are taking medications that might interact with the study drug.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Azienda Ospedaliera Universitaria Meyer IRCCS Florence Italy
Hospital Sant Joan De Deu Barcelona Esplugues De Llobregat Spain
University Of Debrecen Debrecen Hungary
Karolinska University Hospital Solna Sweden
Hopital Beaujon Clichy France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
15.10.2024
Hungary Hungary
Recruiting
15.10.2024
Italy Italy
Recruiting
15.10.2024
Spain Spain
Recruiting
15.10.2024
Sweden Sweden
Not recruiting
15.10.2024

Trial locations

Investigated drugs:

INZ-701 is a medication being studied to see if it can help infants with a condition called ENPP1 Deficiency. This condition affects the levels of a substance in the body called inorganic pyrophosphate (PPi). The trial is looking at whether INZ-701 can increase the levels of PPi and improve the overall survival of the infants.

Investigated diseases:

ENPP1 Deficiency – ENPP1 Deficiency is a rare genetic disorder that affects the body’s ability to regulate calcium and phosphate levels. This condition is caused by mutations in the ENPP1 gene, leading to low levels of inorganic pyrophosphate (PPi), a molecule that helps prevent calcium deposits in the body. As a result, individuals with this deficiency may experience abnormal calcification in blood vessels and other tissues. Over time, this can lead to complications such as heart problems and issues with bone growth. The disease often manifests in infancy or early childhood, with symptoms varying in severity. It is a progressive condition, meaning symptoms can worsen over time.

Trial ID:
2024-512991-36-00
Protocol code:
INZ701-105
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Long-term Safety Study of INZ-701 for Patients with ENPP1 and ABCC6 Deficiencies, Including Pseudoxanthoma Elasticum and Generalized Arterial Calcification of Infancy

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany

  • Study on the Effects and Safety of INZ-701 for Children with ENPP1 Deficiency

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain